Beneficial role of rapamycin in experimental autoimmune myositis.

ABSTRACT:

Introduction

We developed an experimental autoimmune myositis (EAM) mouse model of polymyositis where we outlined the role of regulatory T (Treg) cells. Rapamycin, this immunosuppressant drug used to prevent rejection in organ transplantation, is known to spare Treg. Our aim was to test the efficacy of rapamycin in vivo in this EAM model and to investigate the effects of the drug on different immune cell sub-populations.

Methods

EAM is induced by 3 injections of myosin emulsified in CFA. Mice received rapamycin during 25 days starting one day before myosin immunization (preventive treatment), or during 10 days following the last myosin immunization (curative treatment).

Results

Under preventive or curative treatment, an increase of muscle strength was observed with a

SUBMITTER: Prevel N 

PROVIDER: S-EPMC3827074 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature